AvantiCell Science

About:

AvantiCell Science supplies cell-based products and services for pharmaceutical, agri-biotechnology, and healthcare industries.

Website: http://www.avanticell.com/

Twitter/X: avanticell

Top Investors: EASME - EU Executive Agency for SMEs

Description:

AvantiCell delivers leading-edge solutions for customers wishing to evaluate bio-activity or bio-safety in a wide-range of test materials; from pharmaceuticals, traditional medicines and natural products to medical devices and nano-structured materials. AvantiCell solutions use advanced cell culture technology based on physiologically-relevant human and animal cells. AvantiCell supplies a growing range of human primary cell products which are accessible as cell isolates requiring re-culture within the customer's laboratory or in the form of pre-assembled, cryopreserved models. These products make cell-based analysis available to all customers in a plug-and-play format. AvantiCell also provides its expertise in a range of services ranging from off-the-shelf cell-based assays to specialist cell culture systems customised to meet customers’ requirements. As leaders in cell culture, AvantiCell also offer client-commissioned production of unusual human primary cell types and development of customized analytical models.

Total Funding Amount:

1.31M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Ayr, South Ayrshire, United Kingdom

Founded Date:

2006-01-01

Contact Email:

info(AT)avanticell.com

Founders:

Colin Wilde

Number of Employees:

11-50

Last Funding Date:

2015-11-01

IPO Status:

Private

Industries:

© 2025 bioDAO.ai